Ophthalmic therapeutics m gohari md
This presentation is the property of its rightful owner.
Sponsored Links
1 / 108

Ophthalmic Therapeutics M. Gohari MD PowerPoint PPT Presentation

  • Uploaded on
  • Presentation posted in: General

Ophthalmic Therapeutics M. Gohari MD. Topical Anesthetics. useful for diagnostic and therapeutic procedures, including tonometry, removal of foreign bodies or sutures, gonioscopy, conjunctival scraping, and minor surgical operations on the cornea and conjunctiva.

Download Presentation

Ophthalmic Therapeutics M. Gohari MD

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

Ophthalmic therapeutics m gohari md

Ophthalmic TherapeuticsM. Gohari MD

Ophthalmic therapeutics m gohari md

Topical Anesthetics

Ophthalmic therapeutics m gohari md

  • useful for diagnostic and therapeutic procedures, including tonometry, removal of foreign bodies or sutures, gonioscopy, conjunctival scraping, and minor surgical operations on the cornea and conjunctiva

Ophthalmic therapeutics m gohari md

  • Proparacaine, tetracaine, and benoxinate are the most commonly used topical anesthetics.

  • equivalent anesthetic potency

Ophthalmic therapeutics m gohari md

  • Note:

    Topical anesthetics should never be prescribed for home use, since prolonged application may cause corneal complications

Ophthalmic therapeutics m gohari md

  • Proparacaine Hydrochloride (Ophthaine)

    Preparation: Solution, 0.5%.

    Dosage: 1 drop and repeat as necessary. Onset and duration of action: Anesthesia begins within 20 seconds and lasts 10–15 minutes.

    Comment:Least irritating of the topical anesthetics.

Ophthalmic therapeutics m gohari md

  • Tetracaine Hydrochloride (Pontocaine)

    Preparations: Solution, 0.5%, and ointment, 0.5%.

    Onset and duration of action: Anesthesia occurs within 1 minute and lasts for 15–20 minutes.

    Comment: Stings considerably on instillation

Ophthalmic therapeutics m gohari md

  • Benoxinate Hydrochloride

    Preparation (as Fluress): Solution, 0.4%.

    Onset and duration of action: Anesthesia begins within 1 or 2 minutes and lasts for 10–15 minutes.

Ophthalmic therapeutics m gohari md

Local Anesthetics for Injection

Ophthalmic therapeutics m gohari md

  • Lidocaine, procaine, and mepivacaine are commonly used local anesthetics for eye surgery.

  • Longer-acting agents such as bupivacaine and etidocaineare often mixed with other local anesthetics to prolong the duration of effect.

  • the physician must be aware of the potential systemic toxic action when rapid absorption occurs from the site of the injection, with excessive dosage, or following inadvertent intravascular injection

Ophthalmic therapeutics m gohari md

  • The addition of hyaluronidaseencourages spreading of the anesthetic and shortens the onset to as little as 1 minute. For these reasons, hyaluronidase is commonly used in retrobulbar and peribulbar injections prior to cataract extraction.

  • Injectable anesthetics are used by ophthalmologists most commonly in older patients, who may be susceptible to cardiac arrhythmias; therefore, l-epinephrine should not be used in concentrations greater than 1:200,000

Ophthalmic therapeutics m gohari md

  • Lidocaine Hydrochloride (Xylocaine)

  • Owing to its rapid onset and longer action (1–2 hours), lidocaine has become the most commonly used local anesthetic. It is approximately twice as potent as procaine.

  • Up to 30 mL of 1% solution, without epinephrine, may be used safely. In cataract surgery, 15–20 mL is usually more than adequate. The maximum safe dose is 4.5 mg/kg without epinephrine and 7 mg/kg with epinephrine.

  • Intracamerallidocaine in a 1% solution without preservatives is employed for anesthesia in cataract surgery.

Ophthalmic therapeutics m gohari md

  • Procaine Hydrochloride (Novocaine)

    Duration of action: 45–60 minutes.

Ophthalmic therapeutics m gohari md

  • Mepivacaine Hydrochloride (Carbocaine)

    Duration of action: Approximately 2 hours. Comment: Carbocaine is similar to lidocaine in potency.

    It is usually used in patients who are allergic to lidocaine.

Ophthalmic therapeutics m gohari md

  • Bupivacaine Hydrochloride (Marcaine, Sensorcaine)

  • Onset and duration of action: The onset of action is slower than that of lidocaine, but it persists much longer (up to 6–10 hours).

Ophthalmic therapeutics m gohari md

  • Etidocaine Hydrochloride (Duranest)

  • Onset and duration of action: The onset of action is slower than that of lidocaine but more rapid than that of bupivacaine. The duration of action is approximately twice as long as that of lidocaine (4–8 hours).

Ophthalmic therapeutics m gohari md

Mydriatics &


Ophthalmic therapeutics m gohari md

  • Mydriatics and cycloplegics both dilate the pupil. In addition, cycloplegics cause paralysis of accommodation .

  • Their prime uses are (1) for dilating the pupils to facilitate ophthalmoscopy; (2) for paralyzing the muscles of accommodation, particularly in young patients, as an aid in refraction; and (3) for dilating the pupil and paralyzing the muscles of accommodation in uveitisto prevent synechia formation and relieve pain and photophobia.

Ophthalmic therapeutics m gohari md

  • Since mydriatics and cycloplegics both dilate the pupil, they should be used with extreme caution in eyes with narrow anterior chamber angles since cause angle-closure glaucoma .

Mydriatics sympathomimetics

Mydriatics (Sympathomimetics)

  • Phenylephrine Hydrochloride (Neo-Synephrine)

  • Preparations: Solution, 0.12%, 2.5%, and 10%.

  • Onset and duration of action: The effect usually occurs within 30 minutes after instillation and lasts 2–3 hours.

  • Comment: facilitate ophthalmoscopy, in treatment of uveitis, and to dilate the pupil prior to cataract surgery.

  • The 10% solution should not be used in newborn infants, in cardiac patients, or in patients receiving reserpine, guanethidine, or tricyclic antidepressants, because of increased susceptibility to the vasopressor effects

  • Phenylephrine is a mydriatic with no cycloplegic effect

Ophthalmic therapeutics m gohari md



Atropine sulfate

Atropine Sulfate

  • Preparations: Solution, 0.5–3%; ointment, 0.5% and 1%.

  • Dosage: For refraction in children, instill 1 drop of 0.25–0.5% solution in each eye twice a day for 1 or 2 days before the examination and then 1 hour before the examination;

  • Onset and duration of action: The onset of action is within 30–40 minutes. A maximum effect is reached in about 2 hours. The effect lasts for up to 2 weeks .

  • cycloplegia in children, treatment of iritis. It is also used to maintain a dilated pupil after intraocular surgical procedures.

Ophthalmic therapeutics m gohari md

  • Toxicity:

    Atropine drops must be used with caution to avoid toxic reactions resulting from systemic absorption. Restlessness and excited behavior with dryness and flushing of the skin of the face, dry mouth, fever, inhibition of sweating, and tachycardia are prominent toxic symptoms, particularly in young children.

Scopolamine hydrobromide

Scopolamine Hydrobromide

  • Preparation: Solution, 0.25%.

  • Dosage: 1 drop two or three times daily.

  • Onset and duration of action: Cycloplegia occurs in about 40 minutes and lasts for 3–5 days when scopolamine is used as an aid to refraction .

  • Toxicity: dizziness and disorientation, mainly in older people.

Homatropine hydrobromide


  • Preparations: Solution, 2% and 5%.

  • Dosage: For refraction, 1 drop in each eye and repeat two or three times at intervals of 10–15 minutes.

  • Onset and duration of action: Maximal cycloplegic effect lasts for about 3 hours, but complete recovery time is about 36–48 hours. In certain cases, the shorter action is an advantage over scopolamine and atropine.

  • Toxicity: Sensitivity and side effects associated with the topical instillation of homatropine are rare.

Cyclopentolate hydrochloride cyclogyl

Cyclopentolate Hydrochloride (Cyclogyl)

  • Preparations: Solution, 0.5%, 1%, and 2%.

  • Dosage: For refraction, 1 drop in each eye and repeat after 10 minutes.

  • Onset and duration of action: The onset of dilatation and cycloplegia is within 30–60 minutes. The duration of action is less than 24 hours.

  • Comment:Cyclopentolate is more popular than homatropine and scopolamine in refraction because of its shorter duration of action

  • Occasionally, neurotoxicity may occur, manifested by incoherence, visual hallucinations, slurred speech, and ataxia. These reactions are more common in children.

Tropicamide mydriacyl

Tropicamide (Mydriacyl)

  • Preparations: Solution, 0.5% and 1%; 0.25% with 1% hydroxamphetaminehydrobromide (Paremyd).

  • Dosage: 1 drop of 1% solution two or three times at 5-minute intervals.

  • Onset and duration of action: The time required to reach the maximum cycloplegic effect is usually 20–25 minutes, and the duration of this effect is only 15–20 minutes; therefore, the timing of the examination after instilling tropicamide is important. Complete recovery requires 5–6 hours.

  • Comment:Tropicamide is an effective mydriatic with weak cycloplegic action and is therefore most useful for ophthalmoscopy.

Cyclopentolate hydrochloride phenylephrine hydrochloride cyclomydril

Cyclopentolate Hydrochloride-Phenylephrine Hydrochloride (Cyclomydril)

  • Preparations: Solution, 0.2% cyclopentolate hydrochloride and 1% phenylephrine hydrochloride.

  • Dosage: 1 drop every 5–10 minutes for two or three doses.

  • Onset and duration of action:Mydriasis and some cycloplegia occur within the first 3–6 minutes. The duration of action is usually less than 24 hours.

  • This drug combination is of particular value for pupillary dilation in examination of premature and small infants

Ophthalmic therapeutics m gohari md


Ophthalmic therapeutics m gohari md

  • The concentration used and the frequency of instillation should be individualized on the basis of tonometric measurements. Use the smallest dosage that effectively controls the intraocular pressure and prevents optic nerve damage.

  • All parasympathomimetics decrease intraocular pressure by increasing the outflow of aqueous humor through the trabecular meshwork.

Direct acting cholinergic parasympathomimetic drugs

Direct-Acting Cholinergic (Parasympathomimetic) Drugs

  • Pilocarpine Hydrochloride & Nitrate

    Comment:Pilocarpine was introduced in 1876 and is still a commonly used antiglaucoma drug.

  • Carbachol, Topical

    Comment:Carbachol is poorly absorbed through the cornea and usually is used if pilocarpine is ineffective.

Indirect acting anticholinesterase drugs

Indirect-Acting Anticholinesterase Drugs

  • PhysostigmineSalicylate & Sulfate (Eserine)

    Comment: A high incidence of allergic reactions has limited the use of this old and seldom-used antiglaucoma drug. The miosis produced is extreme; ciliary spasm and myopia are common. Local irritation is common, and phospholine iodide is believed to be cataractogenic in some patients. Pupillary block may occur.

    Echothiophate Iodide (Phospholine Iodide)

    Systemic toxicity may occur in the form of cholinergic stimulation, including salivation, nausea, vomiting, and diarrhea. Ocular side effects include cataract formation, spasm of accommodation, and iris cyst formation.

  • Demecarium Bromide (Humorsol)

Adrenergic sympathomimetic drugs nonspecific

Adrenergic (Sympathomimetic) Drugs; Nonspecific

  • Epinephrine has the advantages of long duration of action (12–72 hours) and no miosis, which is especially important in patients with incipient cataracts (effect on vision not accentuated).

  • effects on both alpha and beta receptor sites.

  • primarily acts by increasing outflow of aqueous humor. However, it also has an ability to decrease production of aqueous humor following long-term use.

Adrenergic sympathomimetic drugs relatively alpha 2 specific

Adrenergic (Sympathomimetic) Drugs; Relatively Alpha 2–Specific

  • Apraclonidine Hydrochloride (Iopidine)

    Preparation: Solution, 0.5% and 1%. Dosage: 1 drop of 1% solution before anterior segment laser treatment and a second drop upon completion of the procedure. One drop of 0.5% solution two or three times a day as short-term adjunctive treatment in glaucoma patients receiving other medications.

    Comment: applied topically for prevention and management of intraocular pressure elevations after anterior segment laser procedures. It is also used as adjunctive therapy in patients on maximally tolerated medical therapy who need further reduction of intraocular pressure.

    Apraclonidine lowers intraocular pressure by decreasing aqueous humor formation. It may also improve aqueous outflow. Unlike clonidine, apraclonidine does not appear to penetrate blood-tissue barriers easily and produces few side effects. The reported systemic side effects include occasional decreases in diastolic blood pressure, bradycardia, and central nervous system symptoms of insomnia, irritability, and decreased libido.

    Ocular side effects include conjunctival blanching, upper lid elevation, mydriasis, and burning.

Ophthalmic therapeutics m gohari md

  • BrimonidineTartrate (Alphagan-P)

    relatively specific alpha 2 adrenergic agonist that lowers intraocular pressure by decreasing aqueous production and perhaps also by increasing outflow through the uveoscleral pathway. It has only minimal effect on heart rate and blood pressure.

    Preparation: Solution, 0.15%. Dosage: 1 drop two or three times daily. Frequently used as a replacement drug in patients unable to tolerate beta-blockers.

    Toxicity: Dry mouth, stinging, and redness are the most common side reactions.

Beta adrenergic blocking sympatholytic drugs

Beta-Adrenergic Blocking (Sympatholytic) Drugs

  • TimololMaleate(Timoptic; Timoptic XE, Betimol)

  • Preparations: Solution, 0.25% and 0.5%; gel, 0.25% and 0.5%.

  • Dosage: 1 drop of 0.25% or 0.5% in each eye once or twice daily if needed. One drop of gel once daily.

  • Comment: nonselective beta-adrenergic blocking agent applied topically for treatment of open-angle glaucoma, aphakic glaucoma, and some types of secondary glaucoma. A single application can lower the intraocular pressure for 12–24 hours. Timolol has been found to be effective in some patients with severe glaucoma inadequately controlled by maximum tolerated antiglaucoma therapy with other drugs. The drug does not affect pupillary size or visual acuity.

  • Although timolol is usually well tolerated, it should be prescribed cautiously for patients with known contraindications to systemic use of beta-adrenergic blocking drugs (eg, asthma, heart failure).

Ophthalmic therapeutics m gohari md

Systemic Side Effects of Timolol

Ophthalmic therapeutics m gohari md

  • If the lacrimal outflow system is functioning, an estimated 80% of a timolol eye drop is absorbed from the nasal mucosa and passes almost directly into the vascular system. This is called the first-order pass effect and is true for all drugs that can be easily absorbed through mucosal tissue in the head.

  • whereas if given orally, its first pass includes absorption via the gastrointestinal tract and then the liver, where 80–90% is detoxified before reaching the right atrium.

  • Cardiopulmonary histories should be taken for candidates of beta-blocker glaucoma therapy. Pulmonary function studies should be considered in patients with bronchoconstrictive disease, and electrocardiograms should be ordered on selected patients with cardiac disease. Patients with known bronchial asthma, chronic respiratory or cardiovascular disease, or sinus bradycardiamay need screening before using timolol.

  • The drug should be used with caution in patients receiving other systemic beta-blocking agents.

Ophthalmic therapeutics m gohari md

  • Betaxolol Hydrochloride (Betoptic; Betoptic S)

    Comment: Its relative 1 receptor selectivity reduces the risk of pulmonary side effects, particularly in patients with reactive airway disease.

  • Levobunolol Hydrochloride (Betagan)

    Comment:Levobunolol is a nonselective 1 and 2 blocker.

  • Metipranolol Hydrochloride (Optipranolol)

    Comment:Metipranolol is a nonselective 1 and 2 blocker .

  • Carteolol Hydrochloride (Ocupress)

Carbonic anhydrase inhibitors orally administered

Carbonic Anhydrase Inhibitors; Orally Administered

  • Inhibition of carbonic anhydrasein the ciliary body reduces the secretion of aqueous.

  • useful in reducing the intraocular pressure in selected cases of open-angle glaucoma and can be used with some effect in angle-closure glaucoma.

  • sulfonamide derivatives. Oral administration produces the maximum effect in approximately 2 hours; intravenous administration, in 20 minutes. The duration of maximal effect is 4–6 hours following oral administration.

  • in patients whose intraocular pressure cannot be controlled with eye drops.

  • They are valuable for this purpose but have many undesirable side effects, including potassium depletion, gastric distress, diarrhea, exfoliative dermatitis, renal stone formation, shortness of breath, fatigue, acidosis, and tingling of the extremities.

  • Since the advent of timolol, topical carbonic anhydrase inhibitors, other newer glaucoma medications, and laser therapy, systemic carbonic anhydrase inhibitors are being used less frequently.

Ophthalmic therapeutics m gohari md

  • Acetazolamide (Diamox)

    Preparations and dosages:Oral: Tablets, 125 mg and 250 mg; give 125–250 mg two to four times a day (dosage not to exceed 1 g in 24 hours). Sustained-release capsules, 500 mg; give 1 capsule once or twice a day. Parenteral: May give 500-mg ampules intramuscularly or intravenously for short periods in patients who cannot tolerate the drug orally.

  • Methazolamide (Neptazane)

  • Dichlorphenamide (Daranide)

Carbonic anhydrase inhibitors topically administered

Carbonic Anhydrase Inhibitors; Topically Administered

  • DorzolamideHydrochloride (Trusopt)

    Preparation: Solution, 2%. Dosage: 1 drop two to four times daily.

    Toxicity: Local reactions include burning and stinging, superficial punctatekeratopathy, and allergic reactions of the conjunctiva. Bitter after-taste is common. Systemic side reactions associated with oral carbonic anhydrase agents are rare.

  • Brinzolamide Ophthalmic Suspension (Azopt)

    Preparation: Suspension, 1%.

Prostaglandin analogs

Prostaglandin Analogs

  • increasing outflow of aqueous humor, mainly via the uveoscleral pathway.

  • Latanoprost (Xalatan)

  • Dosage: 1 drop daily.

  • Travoprost (Travatan)

  • Bimatoprost (Lumigan)

  • Unoprostone Isopropyl (Rescula)

  • Dosage: Two drops daily.

  • Toxicity: All four preparations are associated with increased brown pigmentation of the iris, conjunctival hyperemia,punctate epithelial keratopathy, and a foreign body sensation.

  • In addition, they may aggravate ocular inflammation and have been associated with the development of cystoid macular edema.

Combination topical preparations

Combination Topical Preparations

  • improve compliance but not necessarily resulting in as large a reduction in intraocular pressure as expected from summation of the effects of the individual agents administered separately.

  • Xalacom (latanoprost 0.005% and timolol 0.5%) once daily in the morning,

  • Cosopt (dorzolamide 2% and timolol 0.5%) twice daily

  • ,

  • Combigan (brimonidine 0.2% and timolol 0.5%) twice daily,

  • Duotrav (travoprost 0.004% and timolol 0.5%) once daily,

  • Ganfort (bimatoprost 0.03% and timolol 0.5%) once daily

Osmotic agents

Osmotic Agents

  • reduce intraocular pressure by making the plasma hypertonic to aqueous humor.

  • in the management of acute (angle-closure) glaucoma and occasionally in preoperative or postoperative surgery when reduction of intraocular pressure is indicated. The dosage for all is approximately 1.5 g/kg.

  • Glycerin(Osmoglyn)

    Preparations and dosage: Glycerin is usually given orally as 50% solution with water, orange juice, or flavored normal saline solution over ice .

    Onset and duration of action: Maximum hypotensive effect occurs in 1 hour and lasts 4–5 hours. Toxicity: Nausea, vomiting, and headache occasionally occur.

    Comment: Oral administration and the absence of diuretic effect are significant advantages of glycerin over the other hyperosmotic agents.


    Comment: Unlike glycerin, isosorbide does not produce calories or elevated blood sugar.

  • Mannitol(Osmitrol)

    Preparation: 5–25% solution for injection. Dosage: 1.5–2 g/kg intravenously, usually in 20% concentration.

    Onset and duration of action:Maximum hypotensive effect occurs in about 1 hour and lasts 5–6 hours.

    Comment:Problems with cardiovascular overload and pulmonary edema are more common with this agent because of the large fluid volumes required.

    Urea (Ureaphil)

  • Toxicity: Accidental extravasation at the injection site may cause local reactions ranging from mild irritation to tissue necrosis.

Ophthalmic therapeutics m gohari md

Topical Corticosteroids

Ophthalmic therapeutics m gohari md

  • Indications

  • inflammatory conditions of the anterior segment of the globe: allergic conjunctivitis, uveitis, episcleritis, scleritis, phlyctenulosis, superficial punctatekeratitis, interstitial keratitis, and vernal conjunctivitis.

  • Administration & Dosage

  • The corticosteroids and certain derivatives vary in their anti-inflammatory activity. The relative potency of prednisolone to hydrocortisone is 4 times; of dexamethasone and betamethasone, 25 times.

  • The duration of treatment will vary with the type of lesion and may extend from a few days to several months.

  • Initial therapy for a severely inflamed eye consists of instilling drops every 1 or 2 hours while awake. When a favorable response is observed, gradually reduce the dosage and discontinue as soon as possible.

  • Caution: Side effects of local steroid therapy are exacerbation of herpes simplex keratitis, fungal keratitis, cataract formation (unusual), and open-angle glaucoma (common). These effects are produced to a lesser degree with systemic steroid therapy. Any patient receiving topical ocular corticosteroid therapy or long-term systemic corticosteroid therapy should be under the care of an ophthalmologist

Ophthalmic therapeutics m gohari md

Nonsteroidal Anti-Inflammatory Agents


Ophthalmic therapeutics m gohari md

  • Oral NSAIDs—indomethacin75 mg daily, flurbiprofen 150 mg daily, or ibuprofen 600 mg daily—are the first-line treatment for scleritis. Gastric irritation and hemorrhage are a risk.

  • Topical ophthalmic preparations of several NSAIDs provide ocular bioavailability with little toxicity. These agents act primarily by blocking prostaglandin synthesis through inhibition of cyclooxygenas.

  • flurbiprofen (Ocufen), and suprofen (Profenal) : for inhibition of miosis during cataract surgery.

  • Ketorolac (Acular): seasonal allergic conjunctivitis.

  • Diclofenac(Voltaren) and ketorolac(Acular) were the first topically applied NSAIDs approved for treatment of postoperative inflammation following cataract surgery and for relief of pain and photophobia in patients undergoing laser corneal refractive surgery.

  • In addition, two new topically applied NSAIDs, nepafenac suspension (Nevanac) and Bromfenac solution (Xibrom), are now commercially available.

  • topically applied NSAIDs are often used to prevent and treat cystoid macular edema following cataract surgery.

Ophthalmic therapeutics m gohari md

Other Drugs Used

in the Treatment of

Allergic Conjunctivitis

Ophthalmic therapeutics m gohari md

  • Cromolyn Sodium (Crolom)

    Preparation: Solution, 4%. Dosage: 1 drop four to six times a day.

    Comment:Cromolyn is useful in the treatment of many types of allergic conjunctivitis. Response to therapy usually occurs within a few days but sometimes not until treatment is continued for several weeks.

    Cromolyn acts by inhibiting the release of histamine and slow-reacting substance of anaphylaxis (SRS-A) from mast cells. It is not useful in the treatment of acute symptoms.

  • KetotifenFumarate(Zaditor)

    Dosage: Twice daily.

    Comment:Ketotifen has antihistamine and mast cell–stabilizing activity.

  • LodoxamideTromethamine(Alomide)

    Dosage: 1 drop four times a day.

    Comment:Lodoxamide is a mast cell stabilizer . It is indicated in the treatment of allergic reactions of the external ocular tissues, including vernal conjunctivitis and vernal keratitis. As with cromolyn, a therapeutic response does not usually occur until after a few days of treatment.

Ophthalmic therapeutics m gohari md

  • Nedocromil Sodium (Alocril)

    Comment: rapid onset of an antihistamine and true mast cell–stabilizing activity.

    Olapadine Hydrochloride (Patanol)

    Comment:Olapatadine has both antihistamine and mast cell–stabilizing actions.

    Levocabastine Hydrochloride (Livostin)

    Comment:selective, potent histamine H1-receptor antagonist. It is useful in reducing acute symptoms of allergic conjunctivitis. Relief of symptoms occurs within minutes after application and lasts up to 2 hours.

    EmedastineDifumarate (Emadine)


  • KetorolacTromethamine(Acular)

    only cyclooxygenase inhibitor approved for allergy by the FDA.

    Vasoconstrictors & Decongestants

Ophthalmic therapeutics m gohari md


Ophthalmic Drugs

Ophthalmic therapeutics m gohari md

Topical Antibiotic Solutions & Ointments

Ophthalmic therapeutics m gohari md

  • Bacitracin

    Most gram-positive organisms are sensitive to bacitracin.

    It is not used systemically because of its nephrotoxicity.


    particularly in staphylococcal conjunctivitis.

    It may be used instead of silver nitrate in prophylaxis of


  • Neomycin

    It is best known in ophthalmologic practice as Neosporin, in which it is combined with polymyxin and bacitracin.

    Contact skin sensitivity develops in 5% of patients if the drug is continued for longer than a week.

  • Polymyxin B

    Effective against many gram-negative organisms.

Ophthalmic therapeutics m gohari md

Topical Preparationsof Systemic Antibiotics

Ophthalmic therapeutics m gohari md

  • Topical use of the antibiotics commonly used systemically should be avoided if possible because sensitization of the patient may interfere with future systemic use.

Ophthalmic therapeutics m gohari md

  • Tetracyclines

    limited uses in ophthalmology because their effectiveness is so often impaired by the development of resistant strains. Ointment may be used for prophylaxis of ophthalmianeonatorum.

    Gentamicin (Garamycin, Genoptic, Gentacidin, Gentak)

    corneal ulcers caused by gram-negative organisms. It is also effective against many gram-positive staphylococci but is not effective against streptococci.

    Tobramycin (Tobrex, Aktop)

    Similar antimicrobial activity to gentamicin but more effective against streptococci. Best reserved for treatment of pseudomonas keratitis, for which it is more effective.

    Chloramphenicol (Chloromycetin, Chloroptic)

    effective against a wide variety of gram-positive and gram-negative organisms.

    aplastic anemia have been associated with long-term therapy.

Ophthalmic therapeutics m gohari md

  • Ciprofloxacin (Ciloxan)

    For treatment of conjunctivitis, 1 drop every 2–4 hours. For treatment of corneal ulcers, 1 drop every 15–30 minutes for the first day, 1 drop every hour the second day, and 1 drop every 4 hours thereafter.

    Gatifloxacin (Zymar)

    This fourth-generation fluoroquinolone is more effective against a broader spectrum of gram-positive bacteria and atypical mycobacteria than earlier fluoroquinolones.


    fourth-generation fluoroquinolone

Combination antibiotic agents

Combination Antibiotic Agents

  • mixture of antibiotics and bacteriostatic agents


    most commonly used drugs in the treatment of bacterial conjunctivitis. Their advantages include (1) activity against both gram-positive and gram-negative organisms, (2) relatively low cost, (3) low allergenicity, and (4) the fact that their use is not complicated by secondary fungal infections

  • Sulfacetamide Sodium

Ophthalmic therapeutics m gohari md

Topical Antifungal


Ophthalmic therapeutics m gohari md

  • Natamycin (Natacyn)

    Initial drug of choice for most mycotic corneal ulcers.

    Nystatin (Mycostatin)

  • Nystatin is not available in ophthalmic ointment form, but the dermatologic preparation (100,000 U/g) is not irritating to ocular tissues and can be used in the treatment of fungal infection of the eye.

  • Amphotericin B (Fungizone)

    more effective than nystatin but not available in ophthalmic ointment form. Many patients have extreme ocular discomfort following application of this drug.

  • Miconazole (Monistat)

    in the form of an intravenous preparation that may be instilled directly into the eye.

  • Fluconazole (Diflucan)

Ophthalmic therapeutics m gohari md

Antiviral Agents

Ophthalmic therapeutics m gohari md

  • Idoxuridine (Herplex)

    Used in the treatment of herpes simplex keratitis.

  • Vidarabine (Vira-A)

    In herpetic epithelial keratitis, apply four times daily for 7–10 days. It is effective in some patients unresponsive to idoxuridine. interferes with viral DNA synthesis. The drug is effective against herpetic corneal epithelial disease and has limited efficacy in stromalkeratitis or uveitis. It may cause cellular toxicity and delay corneal regeneration. The cellular toxicity is less than that of idoxuridine.

  • Trifluridine (Viroptic)

    Acts by interfering with viral DNA synthesis. More soluble than either idoxuridine or vidarabine and probably more effective in stromal disease.

  • Acyclovir(Zovirax)

    Preparations: 200, 400, and 800 mg. Comment: Acyclovir is an antiviral agent with inhibitory activity against herpes simplex types 1 and 2, varicella-zoster virus, Epstein-Barr virus, and cytomegalovirus. which inhibits viral DNA polymerase.

    Acyclovir has low toxicity.

Ophthalmic therapeutics m gohari md

  • Ganciclovir (Vitrasert)

    Preparation: Intravitreal implant, 4.5 mg. Comment: treatment of cytomegalovirus retinitis without the adverse effects of systemic therapy.

Diagnostic dye solutions

Diagnostic Dye Solutions

  • Fluorescein Sodium

    for detection of corneal epithelial defects, in applanation tonometry, and in fitting contact lenses.

  • Rose Bengal

    Used in diagnosis of keratoconjunctivitis sicca; the mucous shreds and devitalized corneal epithelium stain with rose bengal.

Tear replacement lubricating agents

Tear Replacement & Lubricating Agents

  • Methylcellulose and related chemicals, polyvinyl alcohol and related chemicals, and gelatin are used in the formulation of artificial tears, ophthalmic lubricants, contact lens solutions, and gonioscopic lens solutions. These agents are particularly useful in the treatment of keratoconjunctivitis sicca

Vasoconstrictors decongestants

Vasoconstrictors & Decongestants

  • The active ingredients in these agents usually are either ephedrine , naphazoline , phenylephrine

  • constrict the superficial vessels of the conjunctiva and relieve redness.

  • They also relieve minor surface irritation and itching of the conjunctiva, which can represent a response to noxious or irritating agents such as smog, swimming pool chlorine, etc.

Corneal dehydrating agents

Corneal Dehydrating Agents

  • reduce corneal edema by creating an osmotic gradient in which the tear film is made hypertonic to the corneal tissues. Temporary clearing of corneal edema results.

  • Preparations: Anhydrous glycerin solution (Ophthalgan); hypertonic sodium chloride 2% and 5% ointment and solution (Absorbonac, Ak-NaCl, Hypersal, Muro-128).

Ophthalmic therapeutics m gohari md

Ocular & Systemic

Side Effects of


Ways to diminish systemic side effects

Ways to Diminish Systemic Side Effects

  • One important principle in avoiding systemic side effects from topical ophthalmic medications is to prevent overdosing. The physician should prescribe the lowest concentration of medication that will be therapeutically effective

Ophthalmic therapeutics m gohari md

  • The eyelids should be kept closed for 3 minutes to prevent blinking.

  • The patient receiving multiple topical medications should wait 10 minutes between doses so that the first drug will not be washed out of the eye by the second.

  • Login